Effects of Modified TCD Regimen on 26 Newly Diagnosed Multiple Myeloma
-
摘要: 目的 观察改良TCD方案(小剂量沙利度胺和地塞米松联合环磷酰胺）治疗初治多发性骨髓瘤的临床疗效。方法应用改良TCD方案6周期治疗26例初治多发性骨髓瘤患者，应用血清蛋白电泳、免疫固定电泳、骨髓细胞形态学和β2-微球蛋白评估治疗效果，同时观察药物的不良反应。结果CR 6例，nCR 7例，PR 5例，轻度反应2 例；总有效率69.2%，总反应率76.9%。化疗不良反应轻，无治疗相关性死亡。结论 改良TCD方案治疗初治多发性骨髓瘤疗效较好，不良反应较少，值得临床推广应用。Abstract: Objective To investigate the efficacy and toxicity of the modified TCD regimen(low-dose thalidomide and dexamethasone in combination with cyclophosphamide）for the treatment of newly diagnosed multiple myeloma. Methods All patients were treated with the modified TCD regimen for 6 courses.Serum protein electrophoresis(M protein and quantity)，immunofixation electrophoresis，bone marrow cell morphology and β2-microglobulin were applied to access the treatment efficacy.The adverse events were also observed. Results When treatments were completed，6 cases achieved complete remission (CR)，7 cases achieved nearly complete remission(nCR)，5 cases achieved partial remission(PR)，2 cases achieved minimal response.Overall remission rate was 69.2%，overall response rate was 76.9%.Toxical and side effect was minimal.No treatment related mortality was observed. Conclusion The modified TCD regimen is a safe and effective regimen which can be used in treatment of patients with newly diagnosed multiple myeloma and worthy for clinical use.
-
Key words:
- Multiple myeloma /
- Thalidomide /
- Low-dose /
- Dexamethasone /
- Newly diagnosed
-
-
[1] Kyle RA，Rajkumar SV.Multiple myeloma [J].Blood，2008，111(6）：2962-2972. [2] Zhang ZN，Shen T.The diagnostic and therapeutic evaluation criteria for hemato logic diseases[M].3rdedition.Beijing:Science Press，2007:234.[张之南，沈悌.血液病学诊断及疗效标准[M] .3版.北京:科学出版社，2007：234.] [3] Durie BG，Harousseau JL，Miguel JS，et al.International uniform response criteria for multiplemyeloma [J].Leukemia，2006，20(9):1467-1473. [4] Singhal S，Mehta J，Desikan R，et al.Antitumor activity of thalidomide in refractory multiplemyeloma [J].N Engl J Med，1999，341(21)：1565-1571. [5] Morabito F，Gentile M，Mazzone C，et al.Therapeutic approaches for newly diagnosed multiplemyeloma patients in the era of novel drugs [J].Eur J Haematol，2010，85(3):181-191. [6] Zhou ZJ，Chen JC，Chen F，et al.The clinical efficacy observation of TCD regimen in thetreatment of newly diagnosed multiple myeloma[J].She Zhi，2006，18(4):277-288.[周章军，陈建才，陈芳，等.TCD方案治疗MM疗效观察 [J].蛇志，2006，18(4）：277-288.] [7] Steurer M，Spizzo G，Mitterer M，et al.Low-dose thalidomide for multiple myeloma：interimanalysis of a compassionate use program [J].Onkologie，2004，27(2):150-154. [8] Murakami H，Handa H，Abe M，et al.Low-dose thalidomide plus low-dose dexamethasone therapy inpatients with refractory multiple myeloma [J].Eur J Haematol，2007，79(3)：234-239. [9] Zangari M，Barlogie B，Thertulien R，et al.Thalidomide and deep vein thrombosis in multiplemyeloma：risk factors and effect on survival [J].Clin Lymphoma，2003，4(1):32-35.
计量
- 文章访问数: 3479
- HTML全文浏览量: 15
- PDF下载量: 718
下载:
